Browse SLC6A9

Summary
SymbolSLC6A9
Namesolute carrier family 6 (neurotransmitter transporter, glycine), member 9
Aliases glyT-1; solute carrier family 6 member 9; Sodium- and chloride-dependent glycine transporter 1
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Multi-pass membrane protein.
Domain PF00209 Sodium
Function

Terminates the action of glycine by its high affinity sodium-dependent reuptake into presynaptic terminals. May play a role in regulation of glycine levels in NMDA receptor-mediated neurotransmission.

> Gene Ontology
 
Biological Process GO:0001505 regulation of neurotransmitter levels
GO:0003333 amino acid transmembrane transport
GO:0006820 anion transport
GO:0006836 neurotransmitter transport
GO:0006865 amino acid transport
GO:0007269 neurotransmitter secretion
GO:0007270 neuron-neuron synaptic transmission
GO:0015711 organic anion transport
GO:0015804 neutral amino acid transport
GO:0015816 glycine transport
GO:0015849 organic acid transport
GO:0023061 signal release
GO:0036233 glycine import
GO:0043090 amino acid import
GO:0043092 L-amino acid import
GO:0046717 acid secretion
GO:0046942 carboxylic acid transport
GO:0060012 synaptic transmission, glycinergic
GO:0061536 glycine secretion
GO:0061537 glycine secretion, neurotransmission
GO:0099531 presynaptic process involved in chemical synaptic transmission
GO:0099643 signal release from synapse
GO:1903825 organic acid transmembrane transport
GO:1905039 carboxylic acid transmembrane transport
Molecular Function GO:0005283 sodium:amino acid symporter activity
GO:0005294 neutral L-amino acid secondary active transmembrane transporter activity
GO:0005326 neurotransmitter transporter activity
GO:0005328 neurotransmitter:sodium symporter activity
GO:0005342 organic acid transmembrane transporter activity
GO:0005343 organic acid:sodium symporter activity
GO:0005416 cation:amino acid symporter activity
GO:0015077 monovalent inorganic cation transmembrane transporter activity
GO:0015081 sodium ion transmembrane transporter activity
GO:0015171 amino acid transmembrane transporter activity
GO:0015175 neutral amino acid transmembrane transporter activity
GO:0015179 L-amino acid transmembrane transporter activity
GO:0015187 glycine transmembrane transporter activity
GO:0015291 secondary active transmembrane transporter activity
GO:0015293 symporter activity
GO:0015294 solute:cation symporter activity
GO:0015370 solute:sodium symporter activity
GO:0015375 glycine:sodium symporter activity
GO:0022804 active transmembrane transporter activity
GO:0046873 metal ion transmembrane transporter activity
GO:0046943 carboxylic acid transmembrane transporter activity
Cellular Component GO:0098793 presynapse
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-425428: Amine compound SLC transporters
R-HSA-442660: Na+/Cl- dependent neurotransmitter transporters
R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-425366: Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
Summary
SymbolSLC6A9
Namesolute carrier family 6 (neurotransmitter transporter, glycine), member 9
Aliases glyT-1; solute carrier family 6 member 9; Sodium- and chloride-dependent glycine transporter 1
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC6A9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSLC6A9
Namesolute carrier family 6 (neurotransmitter transporter, glycine), member 9
Aliases glyT-1; solute carrier family 6 member 9; Sodium- and chloride-dependent glycine transporter 1
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC6A9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLC6A9
Namesolute carrier family 6 (neurotransmitter transporter, glycine), member 9
Aliases glyT-1; solute carrier family 6 member 9; Sodium- and chloride-dependent glycine transporter 1
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC6A9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.8620.0456
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.6040.113
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.310.665
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1250.775
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1260.94
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.440.838
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2410.57
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0170.982
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4250.643
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7760.337
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3080.219
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.010.945
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC6A9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC6A9
Namesolute carrier family 6 (neurotransmitter transporter, glycine), member 9
Aliases glyT-1; solute carrier family 6 member 9; Sodium- and chloride-dependent glycine transporter 1
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC6A9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC6A9
Namesolute carrier family 6 (neurotransmitter transporter, glycine), member 9
Aliases glyT-1; solute carrier family 6 member 9; Sodium- and chloride-dependent glycine transporter 1
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC6A9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC6A9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC6A9
Namesolute carrier family 6 (neurotransmitter transporter, glycine), member 9
Aliases glyT-1; solute carrier family 6 member 9; Sodium- and chloride-dependent glycine transporter 1
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC6A9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC6A9
Namesolute carrier family 6 (neurotransmitter transporter, glycine), member 9
Aliases glyT-1; solute carrier family 6 member 9; Sodium- and chloride-dependent glycine transporter 1
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC6A9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC6A9
Namesolute carrier family 6 (neurotransmitter transporter, glycine), member 9
Aliases glyT-1; solute carrier family 6 member 9; Sodium- and chloride-dependent glycine transporter 1
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC6A9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC6A9
Namesolute carrier family 6 (neurotransmitter transporter, glycine), member 9
Aliases glyT-1; solute carrier family 6 member 9; Sodium- and chloride-dependent glycine transporter 1
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC6A9 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting SLC6A9.
ID Name Drug Type Targets #Targets
DB00145GlycineSmall MoleculeAGXT, AGXT2, ALAS1, ALAS2, BAAT, GARS, GATM, GCAT, GCSH, GLDC, GLR ......30